Pegaptanib (Pfizer, New York City, NY, USA), an RNA aptamer that specifically binds the VEGF165 isoform of VEGF-A, ranibizumab (Genentech), a monoclonal antibody for VEGF, and aflibercept are approved therapies to treat AMD patients. The gene discussed is VEGFA; the disease is age-related macular degeneration.